Related Articles by Review for PMID: 31643256

Year	Number of Results
1963	1
1964	1
1990	1
2000	2
2001	1
2006	1
2009	1
2010	1
2012	3
2014	1
2015	1
2016	2
2017	2
2019	1
2021	4
2022	1
2025	0

1

[No authors listed] [No authors listed] 2021 Oct 14. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2021 Oct 14. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643256 Free Books & Documents. Review.

2

ALDOSTERONE IN CLINICAL MEDICINE.

BIGLIERI EG, SLATON PE Jr. BIGLIERI EG, et al. Calif Med. 1964 Sep;101(3):191-5. Calif Med. 1964. PMID: 14204551 Free PMC article. Review. No abstract available.

3

Aldosterone antagonists in hypertension and heart failure.

Mantero F, Lucarelli G. Mantero F, et al. Ann Endocrinol (Paris). 2000 Feb;61(1):52-60. Ann Endocrinol (Paris). 2000. PMID: 10790593 Review.

4

The spironolactone renaissance.

Doggrell SA, Brown L. Doggrell SA, et al. Expert Opin Investig Drugs. 2001 May;10(5):943-54. doi: 10.1517/13543784.10.5.943. Expert Opin Investig Drugs. 2001. PMID: 11322868 Review.

5

Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?

Bansal S, Lindenfeld J, Schrier RW. Bansal S, et al. Circ Heart Fail. 2009 Jul;2(4):370-6. doi: 10.1161/CIRCHEARTFAILURE.108.821199. Circ Heart Fail. 2009. PMID: 19808361 Review.

6

Aldosterone and volume management in hypertensive heart disease.

Sica DA. Sica DA. Semin Nephrol. 2014 May;34(3):323-32. doi: 10.1016/j.semnephrol.2014.04.007. Epub 2014 Apr 18. Semin Nephrol. 2014. PMID: 25016402 Review.

7

Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C. Lainscak M, et al. Int J Cardiol. 2015 Dec 1;200:25-9. doi: 10.1016/j.ijcard.2015.05.127. Epub 2015 May 21. Int J Cardiol. 2015. PMID: 26404748 Review.

8

Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives.

Manolis AA, Manolis TA, Melita H, Manolis AS. Manolis AA, et al. Vasc Health Risk Manag. 2019 Dec 30;15:571-579. doi: 10.2147/VHRM.S210150. eCollection 2019. Vasc Health Risk Manag. 2019. PMID: 31920323 Free PMC article. Review.

9

Spironolactone: a re-examination.

Skluth HA, Gums JG. Skluth HA, et al. DICP. 1990 Jan;24(1):52-9. doi: 10.1177/106002809002400112. DICP. 1990. PMID: 2405587 Review.

10

[SECONDARY HYPERALDOSTERONISM. PHYSIOPATHOLOGIC, CLINICAL AND THERAPEUTIC CONSIDERATIONS].

DEMARTINIS C, FONZO D. DEMARTINIS C, et al. Clin Ter. 1963 Oct 15;27:51-72. Clin Ter. 1963. PMID: 14097444 Review. Italian. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Related Articles by Review for PMID: 31643256

20 results

Results by year